Battle over drug prices shifts back to the states

The Hill, October 11, 2017
By Rachel Roubein, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: President Trump has derided pharmaceutical companies as “getting away with murder,” but there’s been little action in Washington to rein in the costs of prescription drugs. Some states are taking…

Read More

Congress keeps the heat on 340B

Politico, October 10, 2017
By Sarah Karlin-Smith, citing work by Rachel E. Sachs (Academic Fellow Alumna)

From the article: The House Energy and Commerce Oversight Subcommittee will probe Wednesday into how hospitals and health clinics participating in the 340B discount drug program are using the savings they reap. Nonprofit hospitals and safety net providers…

Read More

Organ Donor Research: Overcoming Challenges, Increasing Opportunities

JAMA, October 10, 2017
James F. Childress, reviewing report co-authored by I. Glenn Cohen (Faculty Director)

From the article: A substantial gap exists between the need for organ transplants and the number of transplants performed each year in the United States. In 2016, 27 630 organs were transplanted from 9971 deceased donors and 5980 additional organs from living…

Read More

‘That should be illegal’: Lawmakers are taking aim at pharma giant Allergan over an unusual deal with a Native American tribe

Business Insider, October 10, 2017
By Lydia Ramsey, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Allergan, the drugmaker behind Botox, is using a tricky workaround to protect patents on one of its drugs — and lawmakers aren't exactly happy about it.  The deal, which passed off the patents for…

Read More

ICER Weekly View 10-06-17

ICER, October 6, 2017
Mitchell Stein, featuring work by Rachel E. Sachs (Academic Fellow Alumna)

From the review: Medicaid’s “best price rule” has long been held up as an obstacle to value pricing – health policy/legal experts take a look and conclude that “the best-price rule is not as serious a problem as it is sometimes made…

Read More

Axios Vitals post from October 4

Axios, October 4, 2017
By Sam Baker, featuring work by Rachel E. Sachs (Academic Fellow Alumna)

From the post: Medicaid and value-based drug deals: New research casts some doubt on the pharmaceutical industry's claim that Medicaid's "best-price" rule inhibits its ability to create contracts that pay for drugs based on…

Read More

Letter to Allergan plc

The House of Representatives Committee on Oversight and Government Reform, October 3, 2017
By Trey Gowdy, Elijah E. Cummings, Dennis A. Ross, and Peter Welch, citing blog post by Rachel E. Sachs (Academic Fellow Alumna)

From the letter: On September 8, 2017, your company announced the trans r of six patents related to its Restasis drug to the Saint Regis Mohawk tribe. 1 The unconventional maneuver has received considerable criticism om the generic competitors challenging the drug's…

Read More

Absent federal action, states take the lead on curbing drug costs

The Washington Post, September 29, 2017
By Shefali Luthra, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Critics see these tailored efforts as falling short or potentially opening other loopholes. Requiring companies to report prices past a certain threshold, for example, might encourage them to consistently set prices just below that level. Maryland’s…

Read More

Welcome to our 2017-2018 Student Fellows!

Petrie-Flom Center, September 14, 2017

The Petrie-Flom Center is pleased to welcome our new 2017-2018 Student Fellows! In the coming year, our fellows will pursue independent scholarly projects related to health law policy, biotechnology, and bioethics under the mentorship of Center faculty…

Read More

FDA Law SSRN Reading List - August 2017

Objective Intent Blog, September 14, 2017
By Erika Lietzan, highlighting work by Rachel E. Sachs (Academic Fellow Alumna)

From the post:  Rachel Sachs, Administering Health Information (forthcoming in Cardozo Law Review).  Professor Sachs (Washington University, in St. Louis) explores the potential…

Read More

FDA Law SSRN Reading List - August 2017

Objective Intent Blog, September 14, 2017
Erika Lietzan, highlighting work by Rachel E. Sachs (Academic Fellow Alumna)

From the post:  Rachel Sachs, Administering Health Information (forthcoming in Cardozo Law Review).  Professor Sachs (Washington…

Read More

The Latest Scam To Protect Sketchy Patents From Patent Office Review: Sell To Native Americans

Techdirt Blog, September 13, 2017
By Mike Masnick, citing Bill of Health post by Rachel E. Sachs (Academic Fellow Alumna)

From the article: [...] Being "self-reliant" means doing something of actual value yourself. It doesn't mean abusing an already questionable loophole in patent law to help giant pharma companies keep their dubious patents and limit the ability…

Read More

Why a Drug Company Is Selling Patents to a Native American Tribe

Gizmodo, September 12, 2017
By Ryan F. Mandelbaum, quoting Rachel E. Sachs (Academic Fellow Alumna)

[...] There is concern that this act may be precedent setting, and other companies may also try and transfer patents to Native American tribes to get around these patent lawsuits. Rachel Sachs, a patent law professor at Washington University…

Read More

Allergan’s deal with the Mohawks raises troubling questions about the future of generics

STAT , September 11, 2017
By Ed Silverman, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: [...] Legal experts, however, say that tribal sovereignty may also thwart generic drug makers from filing a conventional lawsuit. If so, the ramifications may be far-reaching and ominous for consumers,…

Read More

Politico Pulse: What We’re Reading

POLITICO, September 11, 2017
Dan Diamond, citing blog post by Rachel E. Sachs (Academic Fellow Alumna)

Writing at Harvard's Bill of Health blog, law professor Rachel Sachs says that we should be "very, very concerned about what Allergan just did" by making a deal with a Native American tribe to protect a drug patent. More.

Read More

U.S. tribal patent deal could have big impact on generic drug market

Reuters, September 11, 2017
By Jan Wolfe, quoting Rachel E. Sachs (Academic Fellow Alumna)

Challenging patents in federal court is slower and more expensive, though generic companies certainly do it. Teva Pharmaceuticals Inc and other generic drug companies are suing Allergan in federal court seeking a ruling that the latter’s Restasis patents should not…

Read More

PFC Spotlight: Student Fellow Alumna Sara Abiola

Petrie-Flom Center, September 7, 2017

Sara Abiola, PhD, JD, was a Student Fellow during the 2006-2007 academic year, while a second-year law student and first-year health policy doctoral candidate. As part of the…

Read More

Artificial wombs are coming. They could completely change the debate over abortion.

Vox, August 23, 2017
I. Glenn Cohen (Faculty Director)

From the article: There’s a scientific development on the horizon that could upend the abortion debate: artificial wombs. The research remains preliminary,…

Read More

Legal Roundtable: Right-to-work, Chappelle-Nadal’s assassination comment, Charlottesville and more

St. Louis Public Radio, August 23, 2017
Kelly Moffitt, featuring Rachel E. Sachs (Academic Fellow Alumna)

On Wednesday’s St. Louis on the Air, our monthly Legal Roundtable convened to discuss pressing issues of the law. Some of the topics on the table include: Missouri State Senator Maria Chappelle-Nadal’s Facebook comment (since deleted) in which she…

Read More

Obamacare survives its latest threat: Bare counties

POLITICO Pulse, August 21, 2017
Dan Diamond, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article:  Trump quietly signs FDA reauthorization bill. The president didn't hold a signing ceremony on Friday, even though the bill has been one of the few major pieces of legislation…

Read More